Trial · NCT07901621
Combined Versus Multicomponent Training in People With Chronic Kidney Disease Stages 3a and 3b
NCT07901621, Not applicable, Not yet recruiting, University of Brasilia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combined Versus Multicomponent Training in People With Chronic Kidney Disease Stages 3a and 3b. Trials, record NCT07901621. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07901621
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combined Versus Multicomponent Training in People With Chronic Kidney Disease Stages 3a and 3b
- NCT number
- NCT07901621
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 57 participants, estimated
- Lead sponsor
- University of Brasilia
- Conditions
- Chronic Kidney Disease Stage 3A, Chronic Kidney Disease Stage 3B, Chronic Kidney Disease, Non-dialysis
- Interventions
- Combined Training, Multicomponent Training
- First posted
- 2026-10-28
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Peak Oxygen Uptake (VO2peak) | Week 0 (baseline) and week 13 (post-intervention) | Highest 30-second average oxygen uptake during a maximal treadmill test (Bruce protocol) with breath-by-breath gas analysis (Cortex Metalyzer 3B), in mL/kg/min. First outcome in the pre-specified fixed-sequence testing hierarchy. |
| Primary | Resting Systolic Blood Pressure | Week 0 (baseline) and week 13 (post-intervention) | Automatic upper-arm monitor (OMRON HBP-1120-BR); three readings at 1-minute intervals after 5 minutes of seated rest; mean of the last two readings, in mmHg. Second in the testing hierarchy. |
| Primary | Resting Diastolic Blood Pressure | Week 0 (baseline) and week 13 (post-intervention) | Same procedure as systolic blood pressure, in mmHg. Third, in the testing hierarchy. |
| Primary | Physical Health-Related Quality of Life (KDQOL-SF v1.3 Physical Component Summary) | Week 0 (baseline) and week 13 (post-intervention) | Physical Component Summary (PCS) of the SF-36 core of the Kidney Disease Quality of Life Short Form (KDQOL-SF v1.3, Brazilian version), reported as a single summary score on a norm-based T-score scale (general population mean 50, SD 10); higher scores indicate better physical health. Fourth in the testing hierarchy. |
| Primary | Estimated Glomerular Filtration Rate (eGFR) | Week 0 (baseline) and week 13 (post-intervention) | eGFR by the race-free CKD-EPI 2021 creatinine-cystatin C equation, from fasting blood samples, in mL/min/1.73 m2. Fifth in the testing hierarchy. |
| Secondary | Balance (Mini-BESTest) | Week 0 (baseline) and week 13 (post-intervention) | Mini-Balance Evaluation Systems Test total score (0-28; higher = better balance), Brazilian Portuguese version. |
| Secondary | Falls | During the 12-week intervention | Number of participants with at least one fall and fall incidence per group, recorded prospectively with monthly falls calendars (fall defined per ProFaNE consensus). |
| Secondary | Agility and Dynamic Balance (8-Foot Up and Go Test) | Week 0 (baseline) and week 13 (post-intervention) | 8-Foot Up and Go test; best time of two valid attempts, in seconds. |
| Secondary | Handgrip Strength | Week 0 (baseline) and week 13 (post-intervention) | Jamar dynamometer, dominant hand, best of three attempts, in kgf. |
| Secondary | Lower-Limb Muscle Strength (30-Second Chair Stand Test) | Week 0 (baseline) and week 13 (post-intervention) | 30-second chair stand test, number of repetitions. |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07901621
GET https://conductscience.org/api/trials/v1/NCT07901621/registered?page=2